<br />
FEATURED REPORT<br />
Cell-Line<br />
Development<br />
Strategies for Future-<br />
Ready Bioprocessing<br />
APRIL 2025<br />
01 Regulatory Requirements for Human Cell-Line<br />
Development and Cell-Bank Manufacture<br />
Steve Kornher<br />
06 Screen More To Learn More: A Conversation on<br />
Escherichia coli Strain Development<br />
Brian Gazaille with Erik Nordwald<br />
12 Optimizing GS-CHO Expression Vectors for<br />
Biotherapeutic Protein Production<br />
Peter M. O'Callaghan and Yusuf B. Johari<br />
20 Cell-Line Development Is Critical to<br />
the Future of Complex Therapeutics<br />
Eric Chang<br />
24 Resources<br />
Full-Spectrum Microbial<br />
Biomanufacturing<br />
As biologic pipelines grow, so does the demand for<br />
high-performing microbial strains. WuXi Biologics accelerates<br />
your microbial-derived next-generation therapeutics with<br />
expert su<a title="April 2025 - Featured Report page 1" href="https://secure.viewer.zmags.com/publication/0d260962?page=1"> FEATURED REPORT Cell-Line Development Strategie</a>
<a title="April 2025 - Featured Report page 2" href="https://secure.viewer.zmags.com/publication/0d260962?page=2"> Full-Spectrum Microbial Biomanufacturing As biol</a>
<a title="April 2025 - Featured Report page 3" href="https://secure.viewer.zmags.com/publication/0d260962?page=3"> Regulatory Requirements for Human Cell-Line Devel</a>
<a title="April 2025 - Featured Report page 4" href="https://secure.viewer.zmags.com/publication/0d260962?page=4"> Based on those criteria, the FDA has establi</a>
<a title="April 2025 - Featured Report page 5" href="https://secure.viewer.zmags.com/publication/0d260962?page=5"> negligible BSE/TSE risks (class A) and are the pr</a>
<a title="April 2025 - Featured Report page 6" href="https://secure.viewer.zmags.com/publication/0d260962?page=6"> ADVENTITIOUS-AGENT TESTING OF WCBS AND LIMITS OF </a>
<a title="April 2025 - Featured Report page 7" href="https://secure.viewer.zmags.com/publication/0d260962?page=7"> 12 9 CFR 113.46. Detection of Cytopathogen</a>
<a title="April 2025 - Featured Report page 8" href="https://secure.viewer.zmags.com/publication/0d260962?page=8"> Screen More To Learn More A Conversation on Esche</a>
<a title="April 2025 - Featured Report page 9" href="https://secure.viewer.zmags.com/publication/0d260962?page=9"> 7DEOH ɄEscherichia coli–expressed antibody fragme</a>
<a title="April 2025 - Featured Report page 10" href="https://secure.viewer.zmags.com/publication/0d260962?page=10"> Being able to PROVIDE CHOICES helps in moving cel</a>
<a title="April 2025 - Featured Report page 11" href="https://secure.viewer.zmags.com/publication/0d260962?page=11"> 7DEOH ɄExamples of commercially available Escheri</a>
<a title="April 2025 - Featured Report page 12" href="https://secure.viewer.zmags.com/publication/0d260962?page=12"> What does the biopharmaceutical industry n</a>
<a title="April 2025 - Featured Report page 13" href="https://secure.viewer.zmags.com/publication/0d260962?page=13"> Luciferase-labeled Cells Illuminate your assays </a>
<a title="April 2025 - Featured Report page 14" href="https://secure.viewer.zmags.com/publication/0d260962?page=14"> Optimizing Expression Vectors for Biotherapeutic </a>
<a title="April 2025 - Featured Report page 15" href="https://secure.viewer.zmags.com/publication/0d260962?page=15"> inevitably will be complicated by biosynthetic an</a>
<a title="April 2025 - Featured Report page 16" href="https://secure.viewer.zmags.com/publication/0d260962?page=16"> )LJXUH ɄEnhancing synergy between expression-vect</a>
<a title="April 2025 - Featured Report page 17" href="https://secure.viewer.zmags.com/publication/0d260962?page=17"> )LJXUH ɄIncreasing the chances of selecting a hig</a>
<a title="April 2025 - Featured Report page 18" href="https://secure.viewer.zmags.com/publication/0d260962?page=18"> )LJXUH ɄInfluence of gene copy number and relativ</a>
<a title="April 2025 - Featured Report page 19" href="https://secure.viewer.zmags.com/publication/0d260962?page=19"> )LJXUH ɄDifferent expression strengths with novel</a>
<a title="April 2025 - Featured Report page 20" href="https://secure.viewer.zmags.com/publication/0d260962?page=20"> )LJXUH ɄRelative screening workload for a traditi</a>
<a title="April 2025 - Featured Report page 21" href="https://secure.viewer.zmags.com/publication/0d260962?page=21"> 8 Kelsall E, et al. Interplay of Heavy Ch</a>
<a title="April 2025 - Featured Report page 22" href="https://secure.viewer.zmags.com/publication/0d260962?page=22"> Cell-Line Development Is Critical to the Future o</a>
<a title="April 2025 - Featured Report page 23" href="https://secure.viewer.zmags.com/publication/0d260962?page=23"> characterized, stable production cell line is cri</a>
<a title="April 2025 - Featured Report page 24" href="https://secure.viewer.zmags.com/publication/0d260962?page=24"> 7DEOH ɄHistorical performance data — five recent </a>
<a title="April 2025 - Featured Report page 25" href="https://secure.viewer.zmags.com/publication/0d260962?page=25"> Different signal peptides exhibit different </a>
<a title="April 2025 - Featured Report page 26" href="https://secure.viewer.zmags.com/publication/0d260962?page=26"> Industry Resources Checkpoint Inhibitor D</a>
<a title="April 2025 - Featured Report page 27" href="https://secure.viewer.zmags.com/publication/0d260962?page=27"> BioProcess International It's noisy out there! </a>